Baird Downgrades Medpace (MEDP) to Neutral

July 8, 2026 3:13 AM

Baird analyst Eric Coldwell downgraded Medpace (NASDAQ: MEDP) from Outperform to Neutral with a price target of $547.00 (from $477.00).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found